Keep up-to-date with PrECOG by visiting our news page regularly.
PrECOG, LLC, collaborated with global partners on the first large, randomized phase 3 study to show a clinical benefit for CDK4/6 inhibition in HR+, HER2+ metastatic disease, resulting in a 15-month improvement in progression-free survival Philadelphia, PA, January 29, 2026 — PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 […]
Clinical Cancer Research has published a report detailing the safety and efficacy of pelareorep combined with paclitaxel chemotherapy, with or without the checkpoint inhibitor avelumab, for patients whose disease progressed after first-line treatment
Researchers with PrECOG, LLC, are presenting updates and new data at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), occurring in Chicago and online during the first weekend in June.
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence For Immediate Release May 29, 2020 Vienna, Brussels, Chicago, Philadelphia, Neu-Isenburg/Frankfurt, Pittsburgh—The Austrian Breast & Colorectal Cancer Study Group (ABCSG), Alliance Foundation Trials (AFT), the Breast International Group (BIG), PrECOG, […]
The results from the PrE0102 study, a Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy was published by Kornblum N, Zhao F, Manola J, et.al. The article appeared online before print in the Journal of Clinical Oncology on April […]